The increased prevalence of non-alcoholic fatty liver disease in psoriatic patients: A study from South India

Australasian Journal of Dermatology

Volumn 53, Issue 3, 2012, Pages 190-197

  Madanagobalane, Shraddha ^a   Anandan, Sankarasubramanian ^a  

^a SRI RAMACHANDRA UNIVERSITY   (India)

Author keywords

non alcoholic fatty liver disease; psoriasis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA 2 MACROGLOBULIN; APOLIPOPROTEIN A1; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CHOLESTEROL; GLUCOSE; HAPTOGLOBIN; TRIACYLGLYCEROL;

ADULT; ALCOHOL LIVER DISEASE; ARTHRITIS; ARTICLE; BODY MASS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE DURATION; DISEASE SEVERITY; DYSLIPIDEMIA; ECHOGRAPHY; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; INDIA; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PREVALENCE; PSORIASIS SEVERITY INDEX; PSORIASIS VULGARIS; STEATOSIS;

ADULT; AGED; CASE-CONTROL STUDIES; DIABETES MELLITUS; FATTY LIVER; FEMALE; HUMANS; INDIA; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE; PSORIASIS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84865114817     PISSN: 00048380     EISSN: 14400960     Source Type: Journal    
DOI: 10.1111/j.1440-0960.2012.00905.x     Document Type: Article

References (50)

1. Nickoloff BJ, Nestle FO,. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J. Clin. Invest. 2004; 113: 1664-75. (Pubitemid 39071656)
2. Christophers E,. Comorbidities in psoriasis. J. Eur. Acad. Dermatol. Venereol. 2006; 20: 52-5. (Pubitemid 44615011)
3. Mallbris L, Granath F, Hamsten A, et al. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J. Am. Acad. Dermatol. 2006; 54: 614-21.
4. Shapiro J, Cohen AD, David M, et al. The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study. J. Am. Acad. Dermatol. 2007; 56: 629-34. (Pubitemid 46400186)
5. Hensler T, Christophers E,. Disease concomitance in psoriasis. J. Am. Acad. Dermatol. 1995; 32: 982-6.
6. Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J. Am. Acad. Dermatol. 2006; 55: 829-35. (Pubitemid 44556851)
7. Farell GC, Larter CZ,. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43: S100-12.
8. Lonardo A, Loria P, Carulli N,. Concurrent non-alcoholic steatohepatitis and psoriasis. Report of three cases from the POLI.ST.E.N.A. study. Dig. Liver Dis. 2001; 33: 86-7. (Pubitemid 32186183)
9. Miele L, Vallone S, Cefalo C, et al. Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J. Hepatol. 2009; 51: 778-86.
10. Gisondi P, Targher G, Zoppini G, et al. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J. Hepatol. 2009; 51: 758-64.
11. Misra A, Ghosh A, Jhingan AK, et al. The outcome of the consensus meeting held at New Delhi on 15-16 November, 2008 under the Indian Health Ministry.
12. World Health Organization. International Classification of Diseases, 10th Rev. Chapter XII. Diseases of the skin and subcutaneous tissue. Papulosquamous disorders L40 Available from URL: http://apps.who.int/classifications/icd10/ browse/2010/en (Accessed 29 April 2012.)
13. Van de Kerhof PCM,. On the limitation of the psoriasis area severity index (PASI) (letter). Br. J. Dermatol. 1992; 126: 205-6.
14. Finlay AY,. Current severe psoriasis and the rule of tens. Br. J. Dermatol. 2005; 152: 861-7. (Pubitemid 40704922)
15. Taylor W, Gladman D, Heliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006; 54: 2665-73. (Pubitemid 44205029)
16. World Health Organisation. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia. Geneva: World Health Organisation, 2006.
17. Enas EA, Mohan V, Deepa M, et al. The metabolic syndrome and dyslipidemia among Asian Indians: a population with high rates of diabetes and premature coronary artery disease. J. Cardiometab. Syndr. 2007; 2: 267-75.
18. Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in non alcoholic fatty liver disease. Gastroenterology 2002; 123: 745-50. (Pubitemid 34977081)
19. Dowman JK, Tomlinson JW, Newsome PN,. Systemic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment. Pharmacol. Ther. 2011; 33: 524-40.
20. BioPredictive. Biomarqueurs Non-Invasifs des Maladies du Foie. Available from URL: http://www.biopredictive.com (Accessed 29 April 2012.)
21. Berberian KM, van Duijn CM, Hoes AW, et al. Alcohol and mortality. Results from the EPOZ (Epidemiologic Study of Cardiovascular Risk Indicators) follow-up study. Eur. J. Epidemiol. 1994; 10: 587-93. (Pubitemid 24350053)
22. Boza C, Riquelme A, Ibañez L, et al. Predictors of nonalcoholic steatohepatitis (NASH) in obese patients undergoing gastric bypass. Obes. Surg. 2005; 15: 1148-53. (Pubitemid 41390213)
23. Abrams GA, Kunde SS, Lazenby AJ, et al. Portal fibrosis and hepatic steatosis in morbidly obese subjects: a spectrum of nonalcoholic fatty liver disease. Hepatology 2004; 40: 475-83. (Pubitemid 39062866)
24. Leite NC, Salles GF, Araujo AL, et al. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int. 2009; 29: 113-9.
25. Prashanth M, Ganesh HK, Vima MV, et al. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. J. Assoc. Physicians India 2009; 57: 205-10.
26. Parekh S, Anania FA,. Abnormal lipid and glucose metabolism in obesity: implications for non-alcoholic fatty liver disease. Gastroenterology 2007; 132: 2191-207. (Pubitemid 46693752)
27. Donati G, Stagni B, Piscaglia F, et al. Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance. Gut 2004; 53: 1020-3. (Pubitemid 38824162)
28. Kang H, Greenson JK, Omo JT, et al. Metabolic syndrome is associated with greater histologic severity, higher carbohydrate, and lower fat diet in patients with NAFLD. Am. J. Gastroenterol. 2006; 101: 2247-53. (Pubitemid 44477551)
29. Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am. J. Med. 1999; 107: 450-5. (Pubitemid 29528333)
30. Hanley AJ, Karter AJ, Festa A, et al. Factor analysis of metabolic syndrome using directly measured insulin sensitivity: the Insulin Resistance Atherosclerosis Study. Diabetes 2002; 51: 2642-7. (Pubitemid 34827418)
31. Previs SF, Withers DJ, Ren JM, et al. Contrasting effects of IRS-1 versus IRS-2 gene disruption on carbohydrate and lipid metabolism in vivo. J. Biol. Chem. 2000; 275: 38990-4. (Pubitemid 32058910)
32. Samuel VT, Liu Z, Qu X, et al. Mechanisms of hepatic insulin resistance in non-alcoholic fatty liver disease. J. Biol. Chem. 2004; 279: 32345-53. (Pubitemid 39014687)
33. Brenelli SL, Moraes AM, Monte-Allegre S, et al. Insulin resistance in psoriasis. Braz. J. Med. Biol. Res. 1995; 28: 297-301.
34. Boehncke S, Thaci D, Beschmann H,. Psoriasis patients show signs of insulin resistance. Br. J. Dermatol. 2007; 157: 1249-51. (Pubitemid 350115673)
35. Shafiq N, Malhotra S, Pandhi P, et al. Pilot trial: pioglitazone versus placebo in patients with plaque psoriasis (the P6). Int. J. Dermatol. 2005; 44: 328-33. (Pubitemid 40542153)
36. Amarapurkar D, Kamani P, Gupte P, et al. Prevalence of non alcoholic fatty liver disease: population based study. Ann. Hepatol. 2007; 76: 161-3. (Pubitemid 350277193)
37. Mussi A, Bonifati C, Carducci M, et al. Serum TNF- alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis. J. Biol. Regul. Homeost. Agents 1997; 11: 115-8. (Pubitemid 28045966)
38. Jullien D,. Psoriasis pathophysiology. J. Eur. Acad. Dermatol. Venereol. 2006; 20: 10-23.
39. Balding J, Kane D, Livingstone W, et al. Cytokine gene polymorphisms: association with psoriatic arthritis susceptibility and severity. Arthritis Rheum. 2003; 48: 1408-13. (Pubitemid 36554540)
40. Alenius GM, Eriksson C, Rantapää Dahlqvist S,. Interleukin-6 and soluble interleukin-2 receptor alpha-markers of inflammation in patients with psoriatic arthritis? Clin. Exp. Rheumatol. 2009; 27: 120-3.
41. Feldstein AE, Werneburg NW, Canbay A, et al. Free fatty acids promote hepatic lipotoxicity by stimulating TNF- alpha expression via a lysosomal pathway. Hepatology 2004; 40: 185-94. (Pubitemid 38868937)
42. Carter-Kent C, Zein NN, Feldstein AE,. Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment. Am. J. Gastroenterol. 2008; 103: 1036-42. (Pubitemid 351501089)
43. Hotamisligil GS, Budavari A, Murray D, et al. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha. J. Clin. Invest. 1994; 94: 1543-9.
44. Hui JM, Hodge A, Farrell GC, et al. Beyond insulin resistance in NASH: TNF-α or adiponectin? Hepatology 2004; 40: 46-54. (Pubitemid 38868922)
45. Takahashi H, Tsuji H, Takahashi I, et al. Plasma adiponectin and leptin levels in Japanese patients with psoriasis. Br. J. Dermatol. 2008; 159: 1207-14.
46. Shibata S, Tada Y, Hau C, et al. Adiponectin as an anti-inflammatory factor in the pathogenesis of psoriasis: induction of elevated serum adiponectin levels following therapy. Br. J. Dermatol. 2007; 163: 667-70.
47. Silverman JF, O'Brien KF, Long S, et al. Liver pathology in morbidly obese patients with and without diabetes. Am. J. Gastroenterol. 1990; 85: 1349-55. (Pubitemid 20360647)
48. Jarrar MH, Baranova A, Collantes R, et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 2008; 27: 412-21.
49. Ratziu V, Massard J, Charlotte F, et al., LIDO Study Group; CYTOL Study Group. Diagnostic value of biochemical markers (Fibro test-FibroSURE) for prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol. 2006; 6: 6.
50. Poynard T, Ratziu V, Naveau S, et al. The diagnostic value of biomarkers (steato test) for prediction of liver fibrosis. Comp. Hepatol. 2005; 4: 10.